Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 19523: A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

99 years and younger
All genders
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. We would like to rely on Advarra as the IRB …
Learn More

EMBARC

99 years and younger
All genders
The dual primary objectives of the study are: 1) to estimate the safety of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma, and 2) to estimate the feasibility of patient enrollment in such a trial. The dual primary endpoints are safety, as …
Learn More

UPCC 19922 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

99 years and younger
All genders
This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur.
Learn More

Semaglutide Pilot

99 years and younger
All genders
Aim: To conduct a pilot open-label study of semaglutide in lung transplant candidates with obesity. - We will get an estimate of recruitment fraction and retention on study drug. - We will determine preliminary effect estimates of change in weight, percent body fat, skeletal muscle mass, and circulating levels of …
Learn More

ONO MSA

99 years and younger
All genders
Based on its mechanism of action, ONO-2808 has the potential to provide symptomatic improvement and modify disease progression in patients with MSA by promoting remyelination and reducing pathogenic CNS -synuclein accumulation. This initial study of ONO-2808 in MSA patients will generate data to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics …
Learn More

BEACON-IPF

99 years and younger
All genders
This phase 3 study will evaluate bexotograst in patients with IPF. The study will include a CT, PEs, lung function testing, EKGs, vital signs, questionnaires, and safety labs, as well as PK and PD testing.
Learn More

UPCC 33423 A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma (Lumin

99 years and younger
All genders
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Learn More

ZFen+

99 years and younger
All genders
This is a prospective, international, multicenter, non-randomized clinical study to evaluate the safety and effectiveness of the Zenith Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) for the treatment of patients with aortic aneurysms, where the device sealing zone requires fenestrations with …
Learn More

A031501: Phase III randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation

99 years and younger
All genders
We would like to rely on the NCI CIRB as IRB of record for this study. The purpose of this study is to compare any good and bad effects of using a drug called MK-3475 (pembrolizumab) after the removal of muscle invasive bladder cancer.
Learn More

M18-969

99 years and younger
All genders
The primary objective is to assess the safety and efficacy of elagolix (150 mg QD) when used concurrently with a COC containing an estrogen and a progesterone in premenopausal women with endometriosis and associated moderate to severe pain.
Learn More
621 - 630 of 930